Singapore markets closed
  • Straits Times Index

    3,259.14
    -33.59 (-1.02%)
     
  • Nikkei

    27,777.90
    -448.18 (-1.59%)
     
  • Hang Seng

    18,675.35
    -61.09 (-0.33%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • BTC-USD

    17,027.00
    +84.74 (+0.50%)
     
  • CMC Crypto 200

    404.33
    +2.91 (+0.72%)
     
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • Dow

    34,429.88
    +34.87 (+0.10%)
     
  • Nasdaq

    11,461.50
    -20.95 (-0.18%)
     
  • Gold

    1,797.30
    -3.80 (-0.21%)
     
  • Crude Oil

    80.34
    -0.88 (-1.08%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • FTSE Bursa Malaysia

    1,481.80
    -9.71 (-0.65%)
     
  • Jakarta Composite Index

    7,019.64
    -1.16 (-0.02%)
     
  • PSE Index

    6,489.65
    -245.34 (-3.64%)
     

Pfizer (PFE) Stock Moves -0.57%: What You Should Know

Pfizer (PFE) closed the most recent trading day at $43.83, moving -0.57% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.03%. Meanwhile, the Dow lost 1.11%, and the Nasdaq, a tech-heavy index, lost 0.12%.

Prior to today's trading, shares of the drugmaker had lost 5.85% over the past month. This has was narrower than the Medical sector's loss of 6.55% and the S&P 500's loss of 10.4% in that time.

Pfizer will be looking to display strength as it nears its next earnings release, which is expected to be November 1, 2022. The company is expected to report EPS of $1.64, up 22.39% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $22.46 billion, down 6.8% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.54 per share and revenue of $101.13 billion. These totals would mark changes of +47.96% and +24.1%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. Pfizer is currently sporting a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 6.74 right now. Its industry sports an average Forward P/E of 12.19, so we one might conclude that Pfizer is trading at a discount comparatively.

Investors should also note that PFE has a PEG ratio of 0.54 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.75 based on yesterday's closing prices.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 33% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research